MANGALAM2024-04-012024-06-30 MANGALAM2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member MANGALAM2024-06-30 MANGALAM2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532637 MANGALAM NOTLISTED Mangalam Drugs And Organics Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-08-06 INR Lakhs First quarter 17:00:00 19:30:00 2024-08-13 2024-08-13 Not applicable Single segment Manufacturing of Bulk Drugs 2024-04-01 2024-06-30 Unaudited Standalone 765362000.00 202000.00 765564000.00 405344000.00 60728000.00 -61980000.00 95685000.00 37483000.00 38734000.00 183723000.00 759717000.00 5847000.00 0.00 5847000.00 0.00 -21000000.00 -21000000.00 0.00 26847000.00 0.00 0.00 0.00 0.00 26847000.00 -1399000.00 25448000.00 0.00 0.00 1582824800000.00 10 1.70 1.70 0.00 0.00 1.70 1.70 0.00 0.00 0.00 1.The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. 2.The above Unaudited financial results have been reviewed by the Audit Committee and thereafter, were approved and taken on record by the Board of Directors of the Company at their meeting held on August 13, 2024. The Statutory Auidtors have completed Limited Review Report. 3.The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. 4.The figures for the quarter ended 31st March, 2024 are the balancing figures between the Audited figures in respect of the full Financial Year upto March 31, 2024 and the unaudited published Year- to- date figures upto December 31, 2023 being the date of the third quarter of Financial year respectively which were subjected to Limited review. 5.The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Priavte Limited ( First Transferor Company ) and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ( Second Transferor Company ) with Mangalam Drugs and Organics Limited ( Transferee Company ) and their respective shareholders under Section 230 to 232 and other apllicable provisions of Companies Act, 2013. The Scheme is subject to the necessary Stautotry and Regulatory Approvals including the approval of Hon'ble National Company Law Tribunal, the shareholders and Creditors of each of the Companies. As on date, the scheme is pending for disposal at both Stock Exchanges who shall issue No Objection Certificate under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 6.The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation. Other Expenses 183723000.00 Other comprehensive income [Abstract] -1399000.00 -1399000.00 0.00 0.00